secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2026-08-12T20:15:35+00:00
Accession:  0001837607-26-000061
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma reports Q2 2026 cash $3.4M, completes $15.3M offering, FDA Type 2b expected
--------------------------------------------------------------------------------

- Q2 2026 cash and equivalents $3.4M as of June 30, 2026; excludes ~$13.6M net proceeds from July public offering.
- Completed $15.3M underwritten offering in July 2026; milestone warrants could add $34.0M gross; cash runway into Q1 2027.
- FDA BPD Type 2a meeting in Q1 2026 supported ABP-450 analytical approach; Type 2b feedback expected H2 2026.
- Regained NYSE American compliance on Aug 3, 2026.
- Presented comparability data at AAN (April) and AHS (June) meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/0001837607-26-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/aeon-20260812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-26-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer